Sujet non disponible
Généralités
Select a topic to solve related cases or follow a course topic
-
Topic 1Acute COVID-19 in special populations
-
Topic 2First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 3Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 4Adjuvant treatment approaches for MIBC
-
Topic 5NEW --- Molecular diagnostics in the era of targeted therapies for mUCa
-
Topic 6NEW --- Targeted therapies for metastatic UCa in special populations
-
Topic 7NEW --- Handling AEs of targeted therapies for metastatic UCa
-
Topic 8COVID-19 vaccines
-
Topic 9Treatment of acute COVID-19
-
Topic 10Treatment of low and intermediate-risk PCa
-
Topic 11Long COVID
-
Topic 12Prise en charge initiale de la douleur due à l’arthrose
-
Topic 13Arthrose : quelles options envisager après l'échec thérapeutique ?
-
Topic 14Prise en charge de la douleur associée à l'arthrose chez les patients atteints de comorbidités
-
Topic 15Orientation et suivi de la douleur chronique associée à l’arthrose
-
Topic 16High-risk non-metastatic prostate cancer
-
Topic 17Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 18Finding the right ADT for the right patient
-
Topic 19Initial treatment of MIBC
-
Topic 20Biochemical recurrence after radical prostatectomy
-
Topic 21Active surveillance: yes or no?
-
Topic 22Adverse pathology at radical prostatectomy
-
Topic 23Finding the right ADT for the right patient
-
Topic 24Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 25NEW---High-risk non-metastatic prostate cancer
-
Topic 26NEW --- Management of non-metastatic castration-resistant prostate cancer
-
Topic 27NEW --- Treatment selection in mCRPC patients harbouring HRR gene mutations
-
Topic 28Management of non-neurogenic female OAB
-
Topic 29Initial management of nocturia
-
Topic 30Male LUTS: keep on learning
-
Topic 31New hope for patients progressing after prior treatment for mUCa
-
Topic 32Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 33Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 34Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 35First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 36Systemic therapy for HER2-positive early breast cancer
-
Topic 37Systemic therapy for mRCC: second line and beyond
-
Topic 38Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 39Management of small renal masses
-
Topic 40Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 41Systemic therapy for early stage TNBC
-
Topic 42Local therapy for mRCC
-
Topic 43Radiotherapy for early breast cancer
-
Topic 44Management of HER2+ MBC
-
Topic 45Brain metastases in patients with HER2+ breast cancer
-
Topic 46CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 47Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 48Challenges in high-risk NMIBC